rTMS (transcranial magnetic stimulation)
What studies of rTMS (transcranial magnetic stimulation) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 7 findings, all C.
7 outcomes rated · see each below
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 of 5 findings are C.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, rTMS (transcranial magnetic stimulation) might help some people, but research can’t show it yet. For ME/CFS, rTMS (transcranial magnetic stimulation) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- RTMS (transcranial magnetic stimulation) · Long COVID is hereRTMS (transcranial magnetic stimulation) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Cognition (brain fog)3 studies · 25 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (25 in all); not all results were tested against chance; the paper's own effect size: 0.747 (Cohen's d).
Studies with no comparison group3 studies · 25 people with results
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (25 in all)
- Not all results were tested against chance
- The paper's own effect size: 0.747 (Cohen's d)
See the 3 studies
-
- People in the study
- 23 in the study
- Dose
- 1200 pulses, 6 min, at 120% resting motor threshold (RMT), one TMS treatment per day
- Outcome
- PDQ-D-5 score Perceived Deficits Questionnaire – Depression 5 item
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 1 in the study
- Dose
- 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts
- Outcome
- WMS-Logical Memory score Wechsler Memory Scale (WMS)–Third Edition
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 1 in the study
- Dose
- それぞれ10 Hz で1,200 発ずつ,上肢運動野刺激で求められる最小運動強度閾値の90%の強度で賦活した., 週に1 回,連続10 回
- Outcome
- brain fog
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Depression3 studies · 25 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (25 in all); not all results were tested against chance; the paper's own effect size: 1.538 (Cohen's d).
Studies with no comparison group3 studies · 25 people with results
Depression improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on depression in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (25 in all)
- Not all results were tested against chance
- The paper's own effect size: 1.538 (Cohen's d)
See the 3 studies
-
- People in the study
- 23 in the study
- Dose
- 1200 pulses, 6 min, at 120% resting motor threshold (RMT), one TMS treatment per day
- Outcome
- MADRS score Montgomery-Åsberg Depression Rating Scale
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 1 in the study
- Dose
- 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts
- Outcome
- BDI score at 3-month follow-up Beck Depression Inventory
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 1 in the study
- Dose
- 10 Hz with 120% motor threshold, 29 sessions over 6 weeks
- Outcome
- Hamilton Rating Scale for Depression‐17 scores Hamilton Rating Scale for Depression‐17
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue2 studies · 24 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (24 in all); not all results were tested against chance; the paper's own effect size: 0.705 (Cohen's d).
Studies with no comparison group2 studies · 24 people with results
Fatigue improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (24 in all)
- Not all results were tested against chance
- The paper's own effect size: 0.705 (Cohen's d)
See the 2 studies
-
- People in the study
- 23 in the study
- Dose
- 1200 pulses, 6 min, at 120% resting motor threshold (RMT), one TMS treatment per day
- Outcome
- PS score Performance Status
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 1 in the study
- Dose
- それぞれ10 Hz で1,200 発ずつ,上肢運動野刺激で求められる最小運動強度閾値の90%の強度で賦活した., 週に1 回,連続10 回
- Outcome
- 疲労感
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Anxiety1 study · 1 (few people) person received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · twice daily over 5 days for a total of 10 sessions · 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts (few people)
Anxiety improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on anxiety in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts
- Outcome
- BAI score at 3-month follow-up Beck Anxiety Inventory
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 1 (few people) person received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · twice daily over 5 days for a total of 10 sessions · 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts (few people)
Sleep improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on sleep in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts
- Outcome
- PSQI score at 3-month follow-up Pittsburgh Sleep Quality Index (PSQI)
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · 週に1 回,連続10 回 · それぞれ10 Hz で1,200 発ずつ,上肢運動野刺激で求められる最小運動強度閾値の90%の強度で賦活した., 週に1 回,連続10 回 (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
Combination: rTMS (transcranial magnetic stimulation) + Neuromuscular electrical stimulation (NMES)1 in the study
Case report: Dysphagia after COVID-19 infection in a stroke patient-Is neurostimulation a potential management? (2023): feeding tube removal after treatment sessions, better (not tested).
Shown, not counted: rTMS (transcranial magnetic stimulation) was given together with other treatments.
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- それぞれ10 Hz で1,200 発ずつ,上肢運動野刺激で求められる最小運動強度閾値の90%の強度で賦活した., 週に1 回,連続10 回
- Outcome
- 完全復職
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · twice daily over 5 days for a total of 10 sessions · 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- 600 pulses/session for 40 s at 80% of the resting motor threshold (RMT), 20 trains of 10 cTBS bursts
- Outcome
- symptoms gradually lessened
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
ME/CFS
Symptoms
Autonomic symptoms1 study · 30 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (30 in all).
Studies with no comparison group30 in the study · over 2 weeks of hospitalization · bursts containing three pulses at 50 Hz and an intensity of 80% of the active motor threshold repeated at 200-ms intervals (5 Hz), 10 sessions for DLPFC and M1 each over 2 weeks of hospitalization
Autonomic symptoms improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on autonomic symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (30 in all)
See the 1 study
-
- People in the study
- 30 in the study
- Dose
- bursts containing three pulses at 50 Hz and an intensity of 80% of the active motor threshold repeated at 200-ms intervals (5 Hz), 10 sessions for DLPFC and M1 each over 2 weeks of hospitalization
- Outcome
- Orthostatic intolerance
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 30 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (30 in all).
Studies with no comparison group30 in the study · over 2 weeks of hospitalization · bursts containing three pulses at 50 Hz and an intensity of 80% of the active motor threshold repeated at 200-ms intervals (5 Hz), 10 sessions for DLPFC and M1 each over 2 weeks of hospitalization
Pain improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (30 in all)
See the 1 study
-
- People in the study
- 30 in the study
- Dose
- bursts containing three pulses at 50 Hz and an intensity of 80% of the active motor threshold repeated at 200-ms intervals (5 Hz), 10 sessions for DLPFC and M1 each over 2 weeks of hospitalization
- Outcome
- Number of tender points
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 7 (few people) people received rTMS (transcranial magnetic stimulation) Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (7 in all).
Studies with no comparison group7 in the study · six treatment sessions of 25-minute high-frequency rTMS over three days · 10-Hz rTMS was applied in 10-second trains (100 pulses per train) with 50-second intervals between the trains (2,500 pulses per session), six treatment sessions of 25-minute high-frequency rTMS over three days (two sessions per day, excluding the days of admission and discharge) (few people)
No clear change in fatigue.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on fatigue in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (7 in all)
See the 1 study
-
High-frequency rTMS for the Treatment of Chronic Fatigue Syndrome: A Case Series. (2016)
- People in the study
- 7 in the study
- Dose
- 10-Hz rTMS was applied in 10-second trains (100 pulses per train) with 50-second intervals between the trains (2,500 pulses per session), six treatment sessions of 25-minute high-frequency rTMS over three days (two sessions per day, excluding the days of admission and discharge)
- Outcome
- VAS rate Visual Analogue Scale
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 30 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (30 in all).
Studies with no comparison group30 in the study · over 2 weeks of hospitalization · bursts containing three pulses at 50 Hz and an intensity of 80% of the active motor threshold repeated at 200-ms intervals (5 Hz), 10 sessions for DLPFC and M1 each over 2 weeks of hospitalization
Daily functioning improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (30 in all)
See the 1 study
-
- People in the study
- 30 in the study
- Dose
- bursts containing three pulses at 50 Hz and an intensity of 80% of the active motor threshold repeated at 200-ms intervals (5 Hz), 10 sessions for DLPFC and M1 each over 2 weeks of hospitalization
- Outcome
- Performance status score Performance status (PS) grading
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 10 people received rTMS (transcranial magnetic stimulation) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (10 in all); not all results were tested against chance; only people who finished were analysed.
Studies with no comparison group15 in the study · 10 with outcome data · 30 sessions · 1800 pulses, to the left DLPFC (50 Hz bursts applied at 5 Hz, 600 total bursts, 100% MT or adjusted)
Overall symptoms improved.
The evidence is very uncertain about the effect of rTMS (transcranial magnetic stimulation) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (10 in all)
- Not all results were tested against chance
- Only people who finished were analysed
See the 1 study
-
- People in the study
- 15 in the study · 10 with outcome data
- Dose
- 1800 pulses, to the left DLPFC (50 Hz bursts applied at 5 Hz, 600 total bursts, 100% MT or adjusted)
- Outcome
- responded
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
Stopping because of side effects2 studies
We excluded patients who discontinued treatment before the end of the 10 TMS sessions (between the 2nd and 10th sessions: Long-COVID group: 21 patients, Post-Vaccine group: 5 patients, total: 26 patients
Fatigue Potentially Reduces the Effect of Transcranial Magnetic Stimulation on Depression Following COVID-19 and Its Vaccination. (2023)Twelve subjects completed ten sessions of rTMS without adverse events
Effect of Repetitive Transcranial Magnetic Stimulation on Long Coronavirus Disease 2019 with Fatigue and Cognitive Dysfunction. (2023)
Side effects studies reported4 kinds
| Side effect | Studies that reported it |
|---|---|
| Headache | 4 studies |
| Dizziness | 2 studies |
| Fatigue | 1 study |
| Worse symptoms or a flare | 1 study |
All papers
- Comparative Treatment Response to Intermittent Theta Burst Stimulation in Long COVID-Associated Depression Versus Major Depressive Disorder: A Propensity Score-Matched Retrospective Cohort Study.2026 · compared with another group · 609 in the study · 44 started · 44 with outcome data
Summary
This retrospective registry-based cohort study compared intermittent theta burst stimulation (iTBS) in people with Long COVID-associated major depressive disorder and people with primary major depressive disorder. It used real-world data from two TMS clinics in the Tokyo metropolitan area, May 2022–April 2026. A total of 609 patients were assessed; 44 patients with Long COVID-associated depression and 250 patients with primary MDD were eligible, and 1:2 propensity score matching yielded 44 Long COVID patients and 88 matched MDD patients for analysis. All participants received left dorsolateral prefrontal cortex iTBS: 1200 pulses per session, two to three times per week for 20 to 30 sessions, generally at 120% of resting motor threshold with adjustment within 100–120%. Outcomes were MADRS and HAM-D17 improvement, HAM-D17 response, and HAM-D17 remission. Mean MADRS improvement was 38.4% ± 22.1% in the Long COVID group and 61.5% ± 20.3% in the MDD group; HAM-D17 improvement was 36.7% ± 21.8% and 58.4% ± 19.9%. Adjusted differences were −23.0 percentage points for MADRS and −21.8 percentage points for HAM-D17 (both p < 0.001). HAM-D17 response was 31.8% versus 46.6% (OR 0.58, p = 0.176; not statistically significant). HAM-D17 remission was 27.3% versus 61.4% (OR 0.29, p = 0.002). The text reports no adverse events, side effects, or harms-related withdrawals. The authors state that residual unmeasured confounding cannot be excluded.
- Fatigue Potentially Reduces the Effect of Transcranial Magnetic Stimulation on Depression Following COVID-19 and Its Vaccination.2023 · compared with another group · 129 in the study · 60 started · 60 with outcome data
- Involvement of fatigue in the effect of transcranial magnetic stimulation (TMS) on depression following COVID-19 and COVID-19 vaccination: a before-after study2022 · compared with another group · 129 in the study · 46 with outcome data · preprint
Summary
This retrospective before-and-after study used medical records from the Tokyo TMS Clinic, selecting patients from approximately 2000 outpatients between 15 January 2021 and 29 September 2022. The analysis included 46 patients with post-COVID-19 sequelae (Long-Covid) and 14 with long-term COVID-19 vaccine side effects (Post-Vaccine). Patients received transcranial magnetic stimulation (TMS) for 10 treatments, with initial stimulation intensity set at 60-80% of the motor threshold. Outcomes were QIDS, PHQ9, GAD7 and PS (used as an indicator of fatigue symptoms) at the first visit and after 10 TMS treatments. In both groups, QIDS, PHQ9, GAD7 and PS scores improved significantly from the first visit to after 10 treatments; for example, Long-Covid QIDS changed from 6(3-8) to 3(1-5), p=0.0002, and Post-Vaccine QIDS from 7(2.75-9) to 5.5(1-7.5), p<.0001. The paper reports no significant differences between groups in the rate of improvement of PHQ9, GAD7 and PS; an initial univariate difference in ΔQIDS was no longer detected in MANCOVA. PS at the first visit showed a significant positive partial regression coefficient for ΔQIDS. Before the 10-session endpoint, 21 Long-Covid patients and 5 Post-Vaccine patients discontinued treatment; counts of side effects and withdrawals for harms were not reported. The authors note the before-and-after design and possible uncorrected confounding.
- Is the efficacy of repetitive transcranial magnetic stimulation influenced by baseline severity of fatigue symptom in patients with myalgic encephalomyelitis.2020 · compared with another group · 22 in the study · 19 with outcome data
Summary
This cohort study enrolled 22 patients with ME at IUHW Ichikawa Hospital in Japan. Each patient was hospitalized for three or four days to receive 6-8 sessions of high-frequency rTMS, applied at 10 Hz over the DLPFC of the dominant hemisphere; each 18-minute session consisted of 1,800 pulses, and intensity was set at 90% of the measured resting motor threshold. Based on baseline BFI score, patients were divided into a mild group (n = 13) and a severe group (n = 9). BFI and VAS rate were assessed before the first rTMS session, at discharge, and two weeks after discharge. Both groups showed a significant decrease in BFI and VAS rate at discharge and at 2 weeks after discharge (p < 0.05). The improved rate did not differ significantly between groups at discharge (BFI p = 0.65, VAS p = 0.51) or at 2 weeks after discharge (BFI p = 0.37, VAS p = 0.37). No significant correlation was found between baseline BFI and improvement at discharge or 2 weeks after discharge. 19 cases were followed to 2 weeks after discharge. Among the 22 patients, there were no severe adverse events during hospitalization.
- Dual-Target rTMS for Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Pilot Study2025 · no comparison group · 15 in the study · 10 with outcome data
Summary
This pilot study enrolled fifteen female participants with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Participants received dual-target repetitive transcranial magnetic stimulation (rTMS): 1800 pulses of intermittent theta burst stimulation (iTBS) to the left dorsolateral prefrontal cortex and 1500 pulses at 10 Hz to the primary motor cortex, for 30 sessions. After modifications for tolerability, ten completed 30 sessions. There was no comparison group. Symptom domains were assessed with the Fatigue Severity Scale, Brief Pain Inventory, PROMIS Sleep, Inventory of Depressive Symptomatology, and Multidimensional Inventory of Subjective Cognitive Impairment. Among completers, 70% (n=7) responded, defined as ≥30% improvement in fatigue or pain, ≥40% in sleep, ≥10% in cognition, and ≥60% in mood. Baseline EEG was analysed: delta power at F3 negatively correlated with improvement in fatigue (R=-0.64, P=0.048) and sleep (R=-0.85, P=0.001); theta power correlated with fatigue (R=-0.86, P=0.001) and sleep (R=-0.89, P=0.001); alpha power positively correlated with improvement in fatigue (R=0.79, P=0.006) and sleep (R=0.83, P=0.003). The abstract reports no side effects or harms and does not report a comparison group. The authors state that larger trials are needed.
- Static and Kinetic Disequilibrium are Central Neural Signs in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation.2025 · no comparison group · 160 in the study
Summary
The study asked whether repetitive transcranial magnetic stimulation (rTMS) changes static and kinetic disequilibrium in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Consecutive patients who visited Miwa Naika Clinic and could stand and walk were included; 160 ME patients were enrolled. The rTMS study itself was carried out on 13 patients with both static and kinetic disequilibrium. rTMS was delivered to the left dorsolateral prefrontal cortex and primary motor area, with 10 sessions each over 2 weeks of hospitalization; ongoing medications were continued. There was no control group with sham treatment; comparisons were before versus after treatment in the same patients. Outcomes included the Chalder fatigue questionnaire (CFQ), performance status (PS), a 10-min standing test, and recovery from disequilibrium. The CFQ score decreased from 28 ± 3 to 22 ± 5 (difference –6 ± 3, p < 0.01). Eleven (85%) patients recovered from both static and kinetic disequilibrium, with a decrease in PS score of at least 2. Twelve patients completed the 10-min standing test after rTMS versus 4 before; 8 (89%, p < 0.01) of 9 patients with orthostatic intolerance recovered. No patients experienced adverse effects due to the rTMS procedure; in most patients stimulation intensity was lowered due to intolerance to discomfort, headache, and dizziness. The authors state no sham control, inability to separate DLPFC and M1 effects, and no long-term effects.
- Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
Summary
This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.
- Effect of Repetitive Transcranial Magnetic Stimulation on Long Coronavirus Disease 2019 with Fatigue and Cognitive Dysfunction.2023 · no comparison group · 14 in the study · 12 with outcome data
Summary
This retrospective analysis reported on 14 patients with long COVID who completed ten rTMS sessions; 12 were analysed after 2 were excluded because of a history of mental illness. Patients attended an outpatient department from September 8, 2021, to April 11, 2022, and had chronic fatigue and cognitive dysfunction. Treatment was high-frequency rTMS to the occipital and frontal lobes: 1200 10-Hz rTMS to the occipital region followed by another 1200 10-Hz rTMS to the forehead in one session, for ten sessions once every 1–2 weeks (24,000 stimuli in total); the mean study period was 78.6 ± 16.3 days. There was no control group; outcomes were compared before and after treatment in the same patients. BFI decreased from 5.7 ± 2.3 before rTMS to 1.9 ± 1.8 after ten sessions (P < 0.01). AS decreased from 19.2 ± 8.7 to 10.3 ± 7.2 (P < 0.05), and IA rTMS AS was 16.3 ± 7.0, significantly lower than Pre rTMS AS (P < 0.05). WAIS4 components improved: FSIQ 94.6 (10.9) to 104.4 (13.0), VCI 93.5 (9.0) to 100.5 (10.0), PRI 95.4 (11.5) to 106.4 (10.3), WMI 97.9 (17.5) to 105.5 (19.5), and PSI 95.4 (11.5) to 106.4 (10.3), all P < 0.05. Fourteen patients completed ten sessions with no adverse event; during WAIS4 assessment, 4 patients requested discontinuation and 8 were evaluated for Pre/Post. The authors stated limits including no control group, small sample size, possible psychological bias, and possible spontaneous recovery.
- Repetitive transcranial magnetic stimulation ameliorates symptoms in patients with myalgic encephalomyelitis (chronic fatigue syndrome).2023 · no comparison group · 30 in the study
Summary
30 patients with ME (7 men and 23 women) received rTMS over both the left dorsolateral prefrontal cortex and left primary motor area, with 10 sessions for each over 2 weeks of hospitalization. Testing was done before treatment and in the first week after the last session; there were no control patients receiving sham treatment. Measures included performance status for restricted activities of daily living, a 10-min standing test for orthostatic intolerance, disequilibrium, tender points/neuropathic pain or fibromyalgia, and grip power. After treatment, 20 of 30 (67%) had a performance status decrease of at least 2 points; median score fell from 7 to 5 (p < 0.01). Failure to stand for 10 min fell from 12 (40%) to 2 (7%) (p < 0.01), and 10 of 12 (83%) could complete the test. Disequilibrium fell from 17 (57%) to 2 (7%) (p < 0.01) and resolved in 15 of 17 (88%). Median tender points fell from 2 to 0 (p < 0.01); 7 of 10 (70%) had ≥4 tender-point decrease. Grip power <10 kg was present in 4 (13%) before and 2 (7%) after (p = 0.43), and low grip power increased to >10 kg in 2 of 4 (50%). Standing heart rate and blood pressure did not differ significantly. No untoward effects were encountered, and no patient suffered subsequent adverse effects, although stimulation intensity was lowered for complaints of uncomfortableness, headache, and dizziness. Withdrawals due to harms were not reported. Limitations included no sham control and combined DLPFC/M1 stimulation.
- High-frequency rTMS for the Treatment of Chronic Fatigue Syndrome: A Case Series.2016 · no comparison group · 7 in the study
Summary
This pilot case-series study assessed high-frequency rTMS over the dorsolateral prefrontal cortex (DLPFC) in chronic fatigue syndrome (CFS), with no control group. Seven CFS patients referred to the hospital were enrolled and admitted for five days; all started treatment. They received six 25-minute sessions over three days (two per day) of 10-Hz rTMS (2,500 pulses per session, 5,000 per day, 15,000 over three days). Fatigue was measured with the Visual Analogue Scale (VAS) rate and Brief Fatigue Inventory (BFI) before rTMS, after the first session, at discharge and one/two weeks after discharge. Five patients completed the scheduled six sessions; two had stimulation intensity reduced after mild adverse reactions. Mean VAS rate decreased by 17% one hour after the first session (p=0.59); decreases were significant at discharge and one week after discharge (all ps <0.05) but not at two weeks (p=0.21). At discharge, five patients had more than 30% VAS decrease and three more than 50%; six had BFI decrease of more than one point, and mean BFI decrease was significant only at discharge (p<0.05). Five patients had no adverse events; one had nausea, vomiting and headache after two sessions, and one had acute hypotension due to vasovagal reflex during the first session. Symptoms disappeared within several hours without medical intervention; after reduced intensity, neither patient had adverse symptoms, and none of seven had pathological symptoms in the two weeks after discharge. The authors state the study lacked a control group and had a small, heterogeneous sample.
- Evaluating Repetitive Transcranial Magnetic Stimulation for Neuropsychiatric Symptoms in Long COVID: A Case Series.2025 · case report · 5 in the study · 4 with outcome data
Summary
This case series described five patients with long COVID symptoms, ages 52-63 years (3 female patients), who underwent accelerated rTMS using intermittent theta burst stimulation (600 pulses over 3 minutes 20 seconds, 80%-120% of resting motor threshold) to the left dorsolateral prefrontal cortex. Treatment consisted of twice-daily sessions over 20-30 treatments; there was no comparison group. The paper reported immediate clinical outcomes; it was not randomised. Outcomes were PROMIS questionnaires for fatigue, depression, anxiety, cognitive function, and social function at baseline and immediately posttreatment. One patient discontinued immediately due to intolerable scalp pain. Among 4 patients who completed the rTMS course, PROMIS scores showed fatigue decreased from 74.5 to 61.8, depression from 60.3 to 51.5, and anxiety from 62.0 to 54.0; scores increased for cognitive (26.8 to 32.3) and social (31.0 to 32.5) function. These changes were reported as not statistically significant. Subjectively, 3 of 4 patients who completed the rTMS course reported improvements.
- rTMS for post-covid-19 condition: A sham-controlled case series involving iTBS-300 and iTBS-600.2024 · case report · 4 in the study
Summary
This case series examined intermittent theta-burst stimulation (iTBS) for adults with post-COVID-19 condition (PCC). Four participants with PCC after confirmed SARS-CoV-2 infection were enrolled and all four were analysed. Each participant received two sessions of active iTBS-300, two sessions of active iTBS-600 and two sham sessions, pseudo-randomized in a Latin square, with stimulation twice per week on Tuesdays and Thursdays. Outcomes included cognitive tasks, anxiety (GAD-7), quality of life, functional abilities, self-reported executive dysfunction and a custom tolerability survey. Tolerability responses were based on three participants. All three respondents agreed the procedure was well-tolerated and comfortable and would recommend it to others with Long COVID-19; two of three reported tingling at the scalp, and no other tolerability issues were reported. No adverse events occurred in active or sham stimulation. Flanker interference improved relative to baseline in 3 of 4 cases after iTBS-600, quality of life increased in 3 of 4 cases after iTBS-600, and GAD-7 scores decreased in 3 of 4 cases after iTBS-300. Two participants reported improved concentration and thinking during the week of active stimulation. The authors note the small sample, limited sessions, no long-term outcomes and no inferential statistics.
- Neuroinflammatory Alterations in Treatment-Resistant Depression Secondary to Long COVID by Repetitive Transcranial Magnetic Stimulation (rTMS): A Case Report.2024 · case report · 1 in the study
Summary
This case report described one patient with treatment-resistant depression secondary to long COVID who came to the authors' hospital for rTMS treatments. The report aimed to present neuroinflammatory alterations revealed by PET before and after rTMS. The patient received rTMS over the left prefrontal cortex using the NeuroStar system at 10 Hz with 120% motor threshold; she received 29 sessions over 6 weeks. There was no comparison group, and outcomes were assessed before and after treatment. Depressive symptoms measured with Hamilton Rating Scale for Depression‐17 scores improved from 20 to 7 after the treatments. A PET scan using the translocator protein ligand [11C] DAA1106 was performed before and after rTMS and showed that the standardized uptake value ratio of the neuroinflammatory marker [11C] DAA1106 was reduced in the whole brain; the observed changes in each volume of interest ranged from 11.0% to 22.9%. No adverse events were observed. The authors state that further investigation is needed to confirm the reproducibility of the findings and elucidate the underlying mechanisms in a well-designed study.
- A 30-Year-Old Woman with an 8-Week History of Anxiety, Depression, Insomnia, and Mild Cognitive Impairment Following COVID-19 Who Responded to Accelerated Bilateral Theta-Burst Transcranial Magnetic Stimulation Over the Prefrontal Cortex.2023 · case report · 1 in the study
Summary
This case report describes 1 patient, a 30-year-old woman referred to a long-COVID clinic with an 8-week history of anxiety, depression, insomnia, and mild cognitive impairment after COVID-19. She received accelerated bilateral theta-burst transcranial magnetic stimulation over the dorsolateral prefrontal cortex: continuous TBS on the right followed by intermittent TBS on the left, twice daily over 5 days for a total of 10 sessions. There was no comparison group, sham stimulation, or randomisation. The authors measured BAI, BDI, HAMD, PSQI, and WMS subtests. After 10 TBS sessions, scores changed from baseline to follow-up as follows: BAI 4 to 0, BDI 18 to 7, HAMD 10 to 1, PSQI 14 to 10, WMS-Logical Memory 8 to 15, WMS-Faces 10 to 15, WMS-Verbal Paired Associates 12 to 15, and WMS-Family Pictures 8 to 10. At the 3-month follow-up, BAI was 0, BDI 5, HAMD 1, and PSQI 8. The patient felt activities and functions improved, and symptoms gradually lessened. Dizziness and headache were transient and resolved after treatment; no severe adverse effects were reported. The authors state limitations: only 1 patient was evaluated, no sham control, baseline pre-COVID scores unavailable, and confounding not comprehensively excluded.
- Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan.2023 · case report · 23 in the study
Summary
This open-label case series examined transcranial magnetic stimulation for neuropsychiatric symptoms persisting after COVID-19 in 23 patients treated at clinics in the Tokyo metropolitan area as part of a real world TMS registry study. Patients received one TMS treatment per day combining semi-prolonged intermittent theta burst stimulation (1200 pulses, 6 min) to the left dorsolateral prefrontal cortex with 1 Hz-rTMS (600 pulses, 10 min) to the right lateral orbitofrontal cortex, for a total of 20 sessions. There was no comparison group. Measures before and after treatment included MADRS, PHQ-9, Performance Status, and PDQ-D-5. Mean MADRS improved from 21.2 to 9.8; PHQ-9 from 12.9 to 8.2; PS from 5.4 to 4.2; and PDQ-D-5 from 10.0 to 6.3. Approximately 65% (15/23) showed response and approximately 70% (16/23) reached remission. Four out of 23 patients complained of scalp pain at the stimulation site; there were no serious adverse events and no other significant adverse events. None of the patients experienced worsening fatigue, none showed deterioration in cognitive function, and none showed worsening of depressive symptoms. Withdrawals due to harms were not reported. The authors state limitations including open-label design, small sample size, no long-term follow-up, and a Japanese-only sample.
- Long COVID-associated Brain Fog and Therapeutic Intervention Using Repetitive Transcranial Magnetic Stimulation(rTMS)2022 · case report · 1 in the study
Summary
This is a single case report (症例提示) of one patient with long COVID-associated brain fog seen at the author's post-COVID outpatient clinic in Japan. The patient was given high-frequency rTMS at 10 Hz, 1,200 pulses to each target site (bilateral occipital lobes and the right dlPFC), at an intensity of 90% of the minimum motor threshold required for upper-limb motor area stimulation, once weekly for 10 consecutive sessions. There was no comparison group and no randomisation. Brain fog improved markedly immediately after the first rTMS session. At the end of the 10th session, memory-related failures slightly remained while visuospatial failures were absent; the patient could read without difficulty and join conversations without stagnation, the planned demotion was withdrawn and he returned to full work. At follow-up 1 month after the end of rTMS there was no re-exacerbation of symptoms; fatigue was not entirely absent but recovered with one night's sleep, and clock drawing was correct. No adverse events occurred during the rTMS period. The authors state that many questions remain about the specific method — frequency, stimulation intensity, number of sessions and especially the stimulation site — and that their method is not considered optimal.
- Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.2006 · case report · 1 in the study
Summary
This case report described one 39-year-old woman with chronic fatigue syndrome and a coexistent major depression episode, admitted to a psychiatric setting. She was given paroxetine 20 mg/day increased to 40 mg/day, and bupropion was added and gradually increased to 450 mg/day; treatment reached full remission after 6 weeks. There was no comparison group. Symptoms, BDI, MADRS and HAM-D were assessed. After 3 weeks, symptoms improved markedly, reaching full remission after 6 weeks; BDI was 22 at baseline and 5 after 6 weeks, MADRS was 25 and 6, and HAM-D was 22 and 6. On follow-up 6 and 12 months later, symptoms were still absent and she could enter a part time job. After an initial boost of energy, she deteriorated slightly. The authors stated that the report is a case and that controlled studies in larger CFS samples are warranted.
- Case report: Dysphagia after COVID-19 infection in a stroke patient-Is neurostimulation a potential management?2023 · combination: given with other treatments · 1 in the study
Summary
This case report described one 90-year-old man with stroke and post-COVID-19 dysphagia in a rehabilitation ward. He had been weaned from tube feeding 4 months after stroke onset; after COVID-19, a nasogastric tube was reinserted. Swallowing therapy with neurostimulation was given: rTMS at 500 pulses of 10 Hz and 90% resting motor threshold to bilateral pharyngeal cortices, plus NMES at 80 Hz and 12 mA, in a 1-h program 5 days per week for 2 weeks, with conventional swallowing training. Another 10 sessions of swallowing training containing rTMS and NMES were administered. There was no comparison group. Outcomes included feeding tube removal, VFSS findings, FOIS, oral intake, choking, weight, and lung infection. The feeding tube was removed after 20 treatment sessions; the nasogastric tube was removed on October 7, 2022, the 110th day after COVID-19 infection. The report noted improved oral movements, reduced drooling, better laryngeal elevation, stronger volitional cough, less post-swallowing choking, greater swallowing endurance, and improved swallowing ability with increased oral intake and fewer choking episodes. At discharge after the first neurostimulation admission, FOIS was 3 and the nasogastric tube was still necessary. A VFSS on October 7, 2022 showed good bolus transit, less premature leakage, delayed swallowing reflex, good hypopharynx elevation, penetration in thin and thick barium, trace aspiration in thin barium, and limited residue. At one month after tube removal, no lung infection was reported; the patient gained 2 kg after the last discharge.
- Treatment of Chronic Fatigue Syndrome (CFS) in Post-SARS-CoV-2 Infection through combined outpatient Neuromodulation Therapy with Repetitive Transcranial Magnetic Stimulation (rTMS) and Ketamine IV Therapy - A Case Series2022 · combination: given with other treatments · 4 in the study
Summary
In this case series, four patients with post-COVID syndrome, presented diagnostically within the framework of chronic fatigue syndrome, were treated with combined low-frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) at 120% MT over the right dorsolateral prefrontal cortex and ketamine intravenous infusion therapy 0.5mg/kg bw. Treatment lasted 2 to 3 weeks and comprised 20 rTMS sessions and 6 ketamine infusions. There was no comparison group, no sham control, and no blinding. BDI-II, FSS, D2-R and Global Fatigue Skala (VAFS) were measured before and after treatment. Three patients experienced significant improvement; in one patient (Pat. no. 2), male, 22 years old, no improvement in symptoms was observed. For patient no. 1, BDI-II was 9 points before and 4 points after treatment, FSS 45 points and 25 points, VAFS 4 and 7. For patient no. 3, BDI-II was 19 points and 9 points, FSS 57 points and 16 points, VAFS 5 and 10, and working hours increased from 20 to 30 hours per week. For patient no. 4, BDI-II was 22 points and 0 points, FSS 60 points and 12 points, VAFS 2 and 9. For patient no. 2, BDI-II was 22 points and 17 points, FSS 48 points and 47 points, VAFS 4 and 4. Side effects and withdrawals were not reported. The authors state the sample was very small and the influence of the two applied therapy methods cannot be distinguished from each other.
- Systematic Review of Randomized Clinical Trials for the Treatment of Long COVID Syndrome.2026 · systematic review
Summary
This systematic review asked whether treatments for long COVID improve outcomes. It searched MEDLINE through PubMed from 2020 to August 2024 and included 43 randomized clinical trials of people with long COVID. The trials compared interventions with control groups or other treatments and reported a primary outcome. Treatments included nutraceuticals, respiratory muscle training, supervised exercise or pacing, brain stimulation, and medications. Outcomes included symptoms, exercise capacity, Vo2 max, fatigue, cognitive functions, inspiratory pressure, pain, and olfactory and gustatory function. The review reports that all studies testing supervised exercises improved the primary outcome except for one; all but one brain stimulation study improved the primary outcome; and only 2 studies using medications improved the primary outcome. Nirmatrelvir/ritonavir did not improve symptoms; donepezil and lithium did not improve their primary outcomes; thermal water inhalation and a metabolic modulator did not improve the primary outcome. Creatine improved fatigue; vitamin C improved exercise capacity; inspiratory muscle training improved symptoms, exercise capacity and inspiratory pressure. Reported harms included 33% with adverse events (dry mouth) with amantadine, 16% nausea with creatine, 17%–37% adverse events with TMS, two to four percent TMS discontinuation, and 8% inspiratory muscle training discontinuation. The authors state the evidence was mostly low certainty.
- Cognitive and Psychological Symptoms in Post-COVID-19 Condition: A Systematic Review of Structural and Functional Neuroimaging, Neurophysiology, and Intervention Studies.2025 · systematic review
Summary
This systematic review asked whether post-COVID-19 condition (PCC) is associated with structural, functional, and neurophysiological brain changes and evaluated noninvasive brain stimulation (NIBS) and cognitive rehabilitation. It included 78 studies with over 5927 individuals, searched in Web of Science, PubMed, and Embase. Treatments were NIBS, including TMS and tDCS, and cognitive rehabilitation/training; comparisons included active versus sham tDCS and rehabilitation versus no rehabilitation. Outcomes covered cognitive and psychological symptoms, fatigue, quality of life, and cognitive test performance. In a randomized tDCS study, 47 participants with PCC were randomized into active (n=23) and sham (n=24) groups; active tDCS significantly reduced physical fatigue immediately posttreatment and at 1-month follow-up and improved depressive symptoms, but no significant effects were seen for cognitive fatigue or overall quality of life. A 4-week randomized trial found a general reduction in fatigue severity over time across both groups, with within-group improvements significant only in the sham condition; no significant between-group differences were observed for fatigue domains, post-COVID symptom burden, anxiety and depressive symptoms, or cognitive function. Mild to moderate side effects such as tingling or burning sensations were reported in both groups and subsided; no persistent adverse effects were noted at follow-up. Cognitive training with tDCS showed greater improvements in cognitive and psychosocial fatigue, anxiety, and quality of life. Dual-task augmented reality rehabilitation improved cognitive performance in 10 participants compared with 10 who did not receive rehabilitation, with no significant differences for fatigue severity, cardiovascular endurance, or muscular fatigue. TMS studies reported improvements in depression, insomnia, anxiety, neuropsychiatric symptoms, apathy, and fatigue, while a double-blind trial found no significant changes in cognitive test outcomes. Stopping or worsening was not reported. The authors state limitations include heterogeneity and small numbers of high-quality randomized controlled trials.
- Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.2025 · systematic review
Summary
This systematic review asked whether non-invasive or minimally invasive brain stimulation reduces symptoms of post-COVID-19 condition. Four databases were searched through April 2nd, 2024; 19 studies were included, covering tDCS, TMS, tVNS and toACS. Across the included studies, Klirová et al. (33 patients) found no significant intergroup difference in post-COVID-19 symptoms. Santana et al. (70 patients) reported a significant reduction in fatigue and anxiety and an improvement in quality of life with active HD-tDCS compared with sham. Oliver-Mas et al. (47 patients) reported a significant improvement of physical fatigue and depressive symptoms in the active tDCS group compared with sham. Gracia et al. (15 patients) found no significant improvement across groups. Vestito et al. (7 patients) reported a significant improvement of hyposmia comparing tDCS with sham. Sakib et al. (4 patients) detected no significant group differences for rTMS. Badran et al. (13 patients) reported a trend towards mild to moderate effects of tVNS on fatigue. Reported harms included transient burning or tingling during tDCS, mild and transient headache and dizziness, transient tingling on the scalp, transient mild skin irritation with tVNS, and transient pain at the TMS stimulation site. The authors state that sample sizes are small, many studies are case reports, randomization and control groups are often missing, and diagnostic criteria differ.
- Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
Summary
This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
Summary
This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.
- Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.2024 · systematic review
Summary
This systematic review examined interventions for brain fog caused by long-COVID in adults with proven symptoms. It included 17 studies, including a case report of 1 patient and a cohort of 208. Interventions were rehabilitation (cognitive training, telerehabilitation, mindfulness-based programs), noninvasive brain stimulation (transcranial magnetic, direct current, alternating current stimulation, photobiomodulation), hyperbaric oxygen therapy, and PEA-LUT. Treatment duration varied; PEA-LUT was assessed three months after treatment. Some studies compared an intervention with control or treatment as usual, while others reported before-and-after changes. Outcomes included MoCA, MMSE, WAIS4, BNIS, NeuroTrax, CANTAB, TAP/AVLT, CAB, PEBL, and PDQ-D-5. Noninvasive brain stimulation studies all showed improvement in cognitive ability. Hyperbaric oxygen studies showed improvements in cognitive tests and brain perfusion. PEA-LUT improved PRMQ and MoCA scores in treated patients; in one trial mental clouding fell in groups 1 and 3 but not group 2. Rehabilitation results were mixed, with some studies reporting enhancement and others no significant improvement. Adverse effects were mild: scalp pain in 4 out of 23 patients after stimulation; after hyperbaric oxygen, barotrauma n=4, ear pain n=1, palpitations n=3, headache n=1, fever n=1. Rehabilitation and pharmacological treatment had no adverse effects. The authors state limitations include a limited number of studies and high heterogeneity.
- Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment.2026 · review
Summary
This REVIEW ARTICLE summarizes current understanding of Long COVID, including epidemiology, pathophysiology, organ-specific manifestations, and potential therapeutic approaches. It enrolled no patients and gave no treatment: there was no comparison group, no randomisation, no crossover, no follow-up, and no trial registration. The review reports no results of its own. It discusses cited studies separately: an RCT evaluating a 15-day course of Nirmatrelvir/Ritonavir did not demonstrate clear efficacy for established Long COVID; a randomized trial of plasmapheresis failed to demonstrate significant efficacy; an RCT reported greater improvements in Long COVID symptoms with a synbiotic formulation than with placebo; a non-randomized, open-label study involving 60 patients reported FMT recipients had significant improvements in insomnia and reductions in cortisol levels at 12 weeks; open-label studies reported aspirin, clopidogrel, and apixaban may reduce microclot burden and improve fatigue and dyspnea; a retrospective cohort study found pre-existing oral anticoagulant use did not prevent Long COVID and was associated with a higher risk of post-acute sequelae. The authors state no specific therapeutic agents have been approved; rehabilitation efficacy remains largely based on expert opinion, as RCT evidence is still limited; and few pharmacological treatments have been evaluated in randomized controlled trials.
- A Narrative Review of the Efficacy of Long COVID Interventions on Brain Fog, Processing Speed, and Other Related Cognitive Outcomes.2025 · review
Summary
This narrative review asked which interventions have been studied for long COVID-associated neurocognitive deficits. It searched PubMed, Embase, and Scopus and included Twelve studies. Reports covered cognitive training, rTMS, exercise rehabilitation, antihistamines (fexofenadine and famotidine), Brainmax, PEA-LUT, aromatherapy, and CICT. For rTMS, one case study (n = 1) reported improved processing speed and perceptual reasoning scores; a case series (n = 4) reported that 3 of 4 participants improved on behavioral inhibition; a pilot case series (n = 23) reported a statistically significant increase in attention/concentration, memory, and planning/organizational abilities; and a case series (n = 12) reported a statistically significant increase in all four cognitive areas and FSIQ from 94.6 ± 10.9 to 104.4 ± 13.0. The REGAIN trial (585 adults; n = 298 intervention, n = 287 usual care) reported statistically significant improvement in health-related quality of life at 3 months and 12 months and in depression, fatigue, and sleep disturbance, but not in cognitive function at 12 months. Salvucci and colleagues (14 experimental, 13 control) reported that 43% of the experimental group reported vanishing of fatigue and 43% reported vanishing of brain fog; the control group reported no statistically significant improvements across symptoms. Brainmax versus placebo (15 and 15) showed a statistically significant reduction in MFI-20 scores and a slight increase in MoCA scores. CICT (n = 14; 80% of unemployed before CICT returned to work) reported improvements. Authors state limitations include absence of control group, low sample sizes, and no reported effect size calculations. Worsening, stopping, and side effects were not reported.
- CLINICAL ASPECTS OF NEUROLOGICAL MANIFESTATIONS OF LONG COVID AND PROSPECTS FOR PHYSIOTHERAPEUTIC INTERVENTIONS (REVIEW OF LITERATURE)2025 · review
Summary
This literature review examined neurological and neuropsychiatric manifestations of Long COVID and possible physiotherapeutic interventions. It did not report its own patient cohort; it summarized published reports on pulsed electromagnetic field (PEMF) therapy and repetitive transcranial magnetic stimulation (rTMS), including tDCS and TMS. For PEMF, a cited pilot randomized trial reported improvements in functional capacity and quality of life versus placebo; no serious adverse events were noted. A cited clinical observation described immediate improvement in neuromuscular interaction and sustained benefit over six months. For rTMS, a Japanese case series (n>20) suggested reduced depressive symptoms and enhanced cognitive function. A 2023 series documented reductions in chronic fatigue and cognitive slowing. A 2024 pilot (n=4) reported good tolerability and short-term cognitive gains, and single-case reports associated 10 iTBS sessions with mood/cognitive improvements. A cited systematic review of 19 studies found tDCS and TMS as potential modalities but highly inconsistent findings. Harms included transient local sensations during PEMF sessions and transient scalp tingling or headache with TMS; serious adverse events were not reported. The authors stated the evidence base is underpowered pilot data and case series, utility is unproven, and larger randomized trials with standardized protocols are needed.
- Therapeutic use of transcranial magnetic stimulation (TMS) for people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a scoping review2025 · review
Summary
This scoping review asked whether transcranial magnetic stimulation is a therapeutic option for people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The authors searched CINAHL Ultimate, MEDLINE, ScienceDirect, and Scopus from January 1st 1985, to February 16th 2024, and included three articles. All included studies were before-after studies with no control group, conducted in Japan, with sample sizes of 7, 30, and 22 participants and diagnoses of CFS or ME. Treatment length varied across studies. The treatments were high-frequency rTMS over the dorsolateral prefrontal cortex or intermittent Theta Burst Stimulation (iTBS). Outcomes included VAS and BFI fatigue scores, performance status, a standing test, disequilibrium, tender points, and grip strength. In 7 CFS patients, two had a >30% VAS reduction after the first session; at discharge five had a >30% decrease and three a >50% decrease, and six had a BFI reduction of more than one point. In 30 ME patients, 20 had at least a two-point PS decrease and ten had no change; 83% (10/12) completed the standing test, 88% (15/17) of disequilibrium cases improved, and remaining two still had disequilibrium. In 22 ME patients, mild (n=13) and severe (n=9) groups showed no difference in improvement rates; 19 had lower BFI and VAS two weeks post-discharge, with no significant correlation between baseline BFI severity and improvement. In Kakuda et al. [35], two out of seven patients had mild adverse events. No serious adverse effects were reported. Stopping or worsening was not reported in the recorded data. The authors state the evidence is limited by small samples and no control groups.
- Interventions for Long COVID: A Narrative Review.2025 · review
Summary
This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).
- Brain stimulation as a therapy in Long-Covid: A Narrative Review2025 · review
Summary
This narrative review examined noninvasive brain stimulation therapies as possible treatments for long-COVID syndrome, which the authors describe as prevalent among people infected by the virus and without a defined treatment. The authors note that long-COVID is heterogeneous and triggers different symptoms in each patient, with fatigue, cognitive dysfunction, anxiety and depression most frequently reported. They focus on transcranial magnetic stimulation (TMS), while also discussing transcranial direct current stimulation and transcutaneous vagus nerve stimulation. The abstract does not report the number of participants, the number of studies included, a comparison group, randomisation, treatment duration, or follow-up. The authors state that the results of the different studies carried out so far, which have used transcranial direct current stimulation, transcutaneous vagus nerve stimulation or TMS, have shown that these techniques can be effective in treating the clinical symptoms caused by post-COVID syndrome. They conclude that more studies are needed to evaluate this type of therapy on these symptoms, and they state that the great heterogeneity of this syndrome represents a great challenge for public health and a significant socioeconomic cost, requiring investment in the study of new treatment approaches. No side effects, withdrawals, or worsening were reported in the abstract. The abstract does not report patient ratings of treatment.
- The treatment of fatigue by non-invasive brain stimulation.2017 · review
Summary
This comprehensive review searched PubMed and Scopus up to the end of February 2017 for clinical trials of repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation (tDCS) for fatigue. It found 15 studies: 8 tDCS studies and 7 rTMS studies. Six tDCS studies concerned multiple sclerosis and 6 rTMS studies concerned fibromyalgia or chronic fatigue syndrome; the remaining 3 included post-polio syndrome, Parkinson’s disease and amyotrophic lateral sclerosis. The review gives no total number of participants. Trials used anodal tDCS or rTMS protocols, often compared with sham, and fatigue scales including FIS, MFIS, FSS, VAS, BFI and others. Some trials reported significant improvement after active but not sham tDCS or rTMS, for example in multiple sclerosis and fibromyalgia; other trials reported no significant change after both active and sham stimulation. Kakuda et al. was an open-label series of 7 chronic fatigue syndrome patients with 2 dropouts because of adverse events. The abstract counts 6 tDCS studies in multiple sclerosis, while the text says 7 original tDCS studies in this domain. The authors state the level of evidence is too low for a robust conclusion.